Herbal Medicine Guide · Evidence
Chinese Herbal Medicine Research
What randomized trials and systematic reviews have found, where the evidence is thin, and why herbal formulas are hard to study.
Resource Hub / Herbal Medicine Guide / Chinese Herbal Medicine Research
Key points
- A small number of large, placebo-controlled trials of standardized Chinese herbal products have been published in major journals, mostly in heart disease, influenza and prediabetes.
- Cochrane reviews of herbal medicine for period pain, menopausal symptoms and eczema found the evidence promising at best and limited by trial quality.
- Most large trials test modern proprietary capsules, not classical formulas adjusted for an individual.
- Nearly all large trials were run in China, and independent replication elsewhere is rare.
- Trial evidence for one product and one condition does not transfer to other herbs or other conditions.
Why herbal formulas are hard to study
A drug trial tests one compound at one dose. A Chinese herbal formula contains several plants, each with many constituents, and in traditional practice the formula is chosen by pattern and adjusted for the person. Trials have to choose between testing a fixed product, which is easier to blind and reproduce, and testing individualized prescribing, which is closer to practice. Batches of the same herb can also differ in chemical content depending on species, growing conditions and processing.
Reporting has been a second problem. Older trials often did not state the composition, dose or quality control of the formula. A 2017 extension of the CONSORT reporting guideline for Chinese herbal medicine formulas set out what a trial report should include (Cheng et al., 2017).
From herbs to single compounds
The clearest success of herbal research is artemisinin. Tu Youyou's team isolated it from Qing Hao (sweet wormwood) after reviewing classical texts, and it became a standard antimalarial drug (Tu, 2011). This is drug discovery: one purified compound, tested like any other medicine. It shows that the materia medica contains pharmacologically active substances. It does not show that traditional formulas work as traditionally used.
Some groups study a whole formula as a defined multi-herb product. PHY906, a preparation based on a four-herb classical formula, reduced the intestinal toxicity of the chemotherapy drug irinotecan in mice (Lam et al., 2010). That work is preclinical, so it does not establish a benefit in patients.
Large randomized trials
The trials below are among the largest published in general medical journals. In the heart trials, the herbal product was added to standard medical treatment and compared with placebo.
| Trial | Product and condition | Main result | Limits |
|---|---|---|---|
| Wang et al., 2011 | Maxingshigan-yinqiaosan (based on Ma Xing Shi Gan Tang and Yin Qiao San) for H1N1 influenza. 410 people aged 15 to 69. | Median time to fever resolution was 26 hours in the control group. It was 34% shorter with oseltamivir, 37% shorter with the herbal formula and 47% shorter with both (Wang et al., 2011). | Not blinded. Participants were young with mild illness. |
| Li et al., 2013 | Qili Qiangxin capsules for chronic heart failure. 512 patients, 12 weeks. | The blood marker NT-proBNP fell by at least 30% in 47.95% of the herbal group and 31.98% of the placebo group (Li et al., 2013). | A laboratory marker, not survival or hospitalization. Short follow-up. |
| Cheang et al., 2024 (QUEST) | Qiliqiangxin for heart failure with reduced ejection fraction. 3,110 patients, 133 hospitals, median 18.3 months. | Hospitalization for heart failure or cardiovascular death occurred in 25.02% of the herbal group and 30.03% of the placebo group (hazard ratio 0.78, 95% CI 0.68 to 0.90) (Cheang et al., 2024). | Death from any cause did not differ significantly (hazard ratio 0.84, 95% CI 0.70 to 1.01). Conducted in China. |
| Yang et al., 2023 (CTS-AMI) | Tongxinluo for ST-elevation heart attack. 3,777 patients, 124 hospitals. | Major cardiac and cerebrovascular events at 30 days occurred in 3.4% of the herbal group and 5.2% of the placebo group (relative risk 0.64, 95% CI 0.47 to 0.88) (Yang et al., 2023). | More adverse drug reactions with the herbal product (2.1% compared with 1.1%), mainly gastrointestinal. Conducted in China. |
| Lian et al., 2014 | Tianqi capsule for impaired glucose tolerance. 420 people, 12 months. | Diabetes developed in 18.18% of the herbal group and 29.32% of the placebo group, a 32.1% lower risk (Lian et al., 2014). | One year of follow-up. No long-term outcome data. |
| Bensoussan et al., 1998 | Individualized or standard Chinese herbal formulas for irritable bowel syndrome. 116 patients, 16 weeks. | Both herbal groups improved more than placebo. Individualized formulas were no better than the standard formula at the end of treatment, but only the individualized group kept its improvement 14 weeks later (Bensoussan et al., 1998). | Small groups. Conducted in Australia in the 1990s and not repeated at scale. |
These products are modern proprietary formulas. They contain herbs from the classical materia medica, but they are manufactured to a fixed specification and are not the same as a decoction written for one person. They were also studied in serious conditions that need a physician's care, as additions to standard treatment and not as replacements.
Systematic reviews
Cochrane reviews pool many trials and grade the quality of the evidence. For Chinese herbal medicine the conclusions are consistently cautious.
- Period pain. A review of Chinese herbal medicine for primary dysmenorrhoea found promising evidence of benefit, limited by the poor methodological quality of the included trials (Zhu et al., 2008).
- Menopausal symptoms. A review found insufficient evidence that Chinese herbal medicine was better or worse than placebo or hormone therapy for hot flushes, with evidence quality rated very low to moderate (Zhu et al., 2016).
- Eczema. A review of oral and topical Chinese herbal medicine for atopic eczema could not find conclusive evidence of benefit (Gu et al., 2013).
- Low back pain. A review of herbal medicine for low back pain found that some herbal products reduced pain more than placebo, with evidence of moderate quality at best. The products studied were mostly Western herbal preparations, not Chinese formulas (Oltean et al., 2014).
Other trials and reviews by condition
- Constipation. Hemp Seed Pill (Ma Zi Ren Wan) was better than placebo in a 120-person trial, with response rates of 43.3% and 8.3% (Cheng et al., 2011). In a 291-person trial it was better than placebo and not clearly better than senna (68%, 57.7% and 33.0% responded) (Zhong et al., 2019).
- Functional dyspepsia. Rikkunshito, the Japanese form of Liu Jun Zi Tang, missed its primary endpoint in a 247-patient trial (33.6% compared with 23.8% responders) (Suzuki et al., 2014) and improved overall treatment efficacy over placebo in a 125-patient trial (Tominaga et al., 2018).
- Insomnia. A meta-analysis of 12 trials with 1,311 people found better sleep quality scores with Suan Zao Ren Tang. Trial quality varied (Liu et al., 2022).
- Depression. A meta-analysis of 10 trials with 735 people found lower depression scores when the Xiao Yao formula was added to antidepressants. All trials had a moderate to high risk of bias (Man et al., 2014).
- Recurrent urinary tract infection. A Cochrane review of seven small trials with 542 women found possible benefit and could not reach robust conclusions because of poor trial quality (Flower et al., 2015).
- Chronic fatigue. A Cochrane review found no trial of Chinese medicinal herbs that met its quality criteria (Adams et al., 2009).
- Cancer-related fatigue. American ginseng (Xi Yang Shen) did not differ from placebo at four weeks and was better at eight weeks in a 364-person trial (Barton et al., 2013). A 40-patient pilot of Bu Zhong Yi Qi Tang against a waiting list reported less fatigue after two weeks (Jeong et al., 2010).
- Uterine fibroids. A review of 38 trials with 3,816 participants found smaller fibroid volume when Gui Zhi Fu Ling Wan was added to mifepristone. Trial quality was poor (Chen et al., 2014).
- Knee osteoarthritis. A review of 12 trials with 982 participants found possible benefit from Du Huo Ji Sheng Tang added to conventional treatment, with a high risk of bias throughout (Zhang et al., 2016).
The pattern is consistent. The larger placebo-controlled trials show modest effects or mixed results. Reviews that pool many small trials report larger effects and rate the underlying evidence as weak.
Safety research
Research has also identified real harms. Herbs containing aristolochic acid caused kidney failure and urinary tract cancer (Nortier et al., 2000) (Debelle et al., 2008), and herbal and dietary supplements account for about 20% of liver injury cases in United States research data (Navarro et al., 2017). These findings are covered on the safety page.
How to read this evidence
- The strongest trials support specific manufactured products for specific conditions. They do not support Chinese herbal medicine as a whole.
- Where reviews are positive, they usually call for larger and better-designed trials before firm conclusions.
- Traditional indications listed in the Herb Atlas and Formula Atlas describe historical use. Most have not been tested in rigorous trials.
- Research on acupuncture is separate and is summarized on our Acupuncture Research page.
Looking for acupuncture or dry needling?
This herbal guide is for education. We do not prescribe herbal medicine at Morningside Acupuncture. Our licensed acupuncturists treat pain, sports injuries and stress with acupuncture and dry needling on the Upper West Side, in sessions of 45 to 60 minutes.
Book Your First VisitMore in the herbal medicine guide
References
Adams, D., Wu, T., Yang, X., Tai, S., & Vohra, S. (2009). Traditional Chinese medicinal herbs for the treatment of idiopathic chronic fatigue and chronic fatigue syndrome. Cochrane Database of Systematic Reviews, (4), CD006348. https://doi.org/10.1002/14651858.CD006348.pub2
Barton, D. L., Liu, H., Dakhil, S. R., Linquist, B., Sloan, J. A., Nichols, C. R., McGinn, T. W., Stella, P. J., Seeger, G. R., Sood, A., & Loprinzi, C. L. (2013). Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2. Journal of the National Cancer Institute, 105(16), 1230-1238. https://doi.org/10.1093/jnci/djt181
Bensoussan, A., Talley, N. J., Hing, M., Menzies, R., Guo, A., & Ngu, M. (1998). Treatment of irritable bowel syndrome with Chinese herbal medicine: A randomized controlled trial. JAMA, 280(18), 1585-1589. https://doi.org/10.1001/jama.280.18.1585
Cheang, I., Yao, W., Zhou, Y., Zhu, X., Ni, G., Lu, X., Liao, S., Gao, R., Zhou, F., Shen, J., Leung, A. Y. L., Jiang, M., Kong, H., Bai, L., Mahemuti, A., Yuan, H., Dong, Y. G., Wong, C. K., Xu, Q., . . . QUEST Trial Committees and Investigators. (2024). The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: A randomized, double-blind, placebo-controlled trial. Nature Medicine, 30(8), 2295-2302. https://doi.org/10.1038/s41591-024-03169-2
Chen, N. N., Han, M., Yang, H., Yang, G. Y., Wang, Y. Y., Wu, X. K., & Liu, J. P. (2014). Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: A systematic review of randomised clinical trials. BMC Complementary and Alternative Medicine, 14, 2. https://doi.org/10.1186/1472-6882-14-2
Cheng, C. W., Bian, Z. X., Zhu, L. X., Wu, J. C. Y., & Sung, J. J. Y. (2011). Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. The American Journal of Gastroenterology, 106(1), 120-129. https://doi.org/10.1038/ajg.2010.305
Cheng, C. W., Wu, T. X., Shang, H. C., Li, Y. P., Altman, D. G., Moher, D., Bian, Z. X., & CONSORT-CHM Formulas 2017 Group. (2017). CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration. Annals of Internal Medicine, 167(2), 112-121. https://doi.org/10.7326/M16-2977
Debelle, F. D., Vanherweghem, J. L., & Nortier, J. L. (2008). Aristolochic acid nephropathy: A worldwide problem. Kidney International, 74(2), 158-169. https://doi.org/10.1038/ki.2008.129
Flower, A., Wang, L. Q., Lewith, G., Liu, J. P., & Li, Q. (2015). Chinese herbal medicine for treating recurrent urinary tract infections in women. Cochrane Database of Systematic Reviews, 2015(6), CD010446. https://doi.org/10.1002/14651858.CD010446.pub2
Gu, S., Yang, A. W., Xue, C. C., Li, C. G., Pang, C., Zhang, W., & Williams, H. C. (2013). Chinese herbal medicine for atopic eczema. Cochrane Database of Systematic Reviews, (9), CD008642. https://doi.org/10.1002/14651858.CD008642.pub2
Jeong, J. S., Ryu, B. H., Kim, J. S., Park, J. W., Choi, W. C., & Yoon, S. W. (2010). Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Integrative Cancer Therapies, 9(4), 331-338. https://doi.org/10.1177/1534735410383170
Lam, W., Bussom, S., Guan, F., Jiang, Z., Zhang, W., Gullen, E. A., Liu, S. H., & Cheng, Y. C. (2010). The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Science Translational Medicine, 2(45), 45ra59. https://doi.org/10.1126/scitranslmed.3001270
Li, X., Zhang, J., Huang, J., Ma, A., Yang, J., Li, W., Wu, Z., Yao, C., Zhang, Y., Yao, W., Zhang, B., Gao, R., & Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group. (2013). A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. Journal of the American College of Cardiology, 62(12), 1065-1072. https://doi.org/10.1016/j.jacc.2013.05.035
Lian, F., Li, G., Chen, X., Wang, X., Piao, C., Wang, J., Hong, Y., Ba, Z., Wu, S., Zhou, X., Lang, J., Liu, Y., Zhang, R., Hao, J., Zhu, Z., Li, H., Fang Liu, H., Cao, A., Yan, Z., . . . Tong, X. (2014). Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: A double-blind, randomized, placebo-controlled, multicenter trial. The Journal of Clinical Endocrinology and Metabolism, 99(2), 648-655. https://doi.org/10.1210/jc.2013-3276
Liu, X. X., Ma, Y. Q., Wang, Y. G., Zhong, F. X., Yin, X. P., & Zhang, Q. M. (2022). Suanzaoren Decoction for the treatment of chronic insomnia: A systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 26(22), 8523-8533. https://doi.org/10.26355/eurrev_202211_30388
Man, C., Li, C., Gong, D., Xu, J., & Fan, Y. (2014). Meta-analysis of Chinese herbal Xiaoyao formula as an adjuvant treatment in relieving depression in Chinese patients. Complementary Therapies in Medicine, 22(2), 362-370. https://doi.org/10.1016/j.ctim.2014.02.001
Nortier, J. L., Martinez, M. C., Schmeiser, H. H., Arlt, V. M., Bieler, C. A., Petein, M., Depierreux, M. F., De Pauw, L., Abramowicz, D., Vereerstraeten, P., & Vanherweghem, J. L. (2000). Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). The New England Journal of Medicine, 342(23), 1686-1692. https://doi.org/10.1056/NEJM200006083422301
Oltean, H., Robbins, C., van Tulder, M. W., Berman, B. M., Bombardier, C., & Gagnier, J. J. (2014). Herbal medicine for low-back pain. Cochrane Database of Systematic Reviews, (12), CD004504. https://doi.org/10.1002/14651858.CD004504.pub4
Suzuki, H., Matsuzaki, J., Fukushima, Y., Suzaki, F., Kasugai, K., Nishizawa, T., Naito, Y., Hayakawa, T., Kamiya, T., Andoh, T., Yoshida, H., Tokura, Y., Nagata, H., Kobayakawa, M., Mori, M., Kato, K., Hosoda, H., Takebayashi, T., Miura, S., ... Rikkunshito study group. (2014). Randomized clinical trial: Rikkunshito in the treatment of functional dyspepsia - a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterology and Motility, 26(7), 950-961. https://doi.org/10.1111/nmo.12348
Tominaga, K., Sakata, Y., Kusunoki, H., Odaka, T., Sakurai, K., Kawamura, O., Nagahara, A., Takeuchi, T., Fujikawa, Y., Oshima, T., Kato, M., Furuta, T., Murakami, K., Chiba, T., Miwa, H., Kinoshita, Y., Higuchi, K., Kusano, M., Iwakiri, R., ... Arakawa, T. (2018). Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study). Neurogastroenterology and Motility, 30(7), e13319. https://doi.org/10.1111/nmo.13319
Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Medicine, 17(10), 1217-1220. https://doi.org/10.1038/nm.2471
Wang, C., Cao, B., Liu, Q. Q., Zou, Z. Q., Liang, Z. A., Gu, L., Dong, J. P., Liang, L. R., Li, X. W., Hu, K., He, X. S., Sun, Y. H., An, Y., Yang, T., Cao, Z. X., Guo, Y. M., Wen, X. M., Wang, Y. G., Liu, Y. L., & Jiang, L. D. (2011). Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: A randomized trial. Annals of Internal Medicine, 155(4), 217-225. https://doi.org/10.7326/0003-4819-155-4-201108160-00005
Yang, Y., Li, X., Chen, G., Xian, Y., Zhang, H., Wu, Y., Yang, Y., Wu, J., Wang, C., He, S., Wang, Z., Wang, Y., Wang, Z., Liu, H., Wang, X., Zhang, M., Zhang, J., Li, J., An, T., . . . CTS-AMI Investigators. (2023). Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: The CTS-AMI randomized clinical trial. JAMA, 330(16), 1534-1545. https://doi.org/10.1001/jama.2023.19524
Zhang, W., Wang, S., Zhang, R., Zhang, Y., Li, X., Lin, Y., & Wei, X. (2016). Evidence of Chinese herbal medicine Duhuo Jisheng decoction for knee osteoarthritis: A systematic review of randomised clinical trials. BMJ Open, 6(1), e008973. https://doi.org/10.1136/bmjopen-2015-008973
Zhong, L. L. D., Cheng, C. W., Kun, W., Dai, L., Hu, D. D., Ning, Z. W., Xiao, H. T., Lin, C. Y., Zhao, L., Huang, T., Tian, K., Chan, K. H., Lam, T. W., Chen, X. R., Wong, C. T., Li, M., Lu, A. P., Wu, J. C. Y., & Bian, Z. X. (2019). Efficacy of MaZiRenWan, a Chinese herbal medicine, in patients with functional constipation in a randomized controlled trial. Clinical Gastroenterology and Hepatology, 17(7), 1303-1310.e18. https://doi.org/10.1016/j.cgh.2018.04.005
Zhu, X., Liew, Y., & Liu, Z. L. (2016). Chinese herbal medicine for menopausal symptoms. Cochrane Database of Systematic Reviews, (3), CD009023. https://doi.org/10.1002/14651858.CD009023.pub2
Zhu, X., Proctor, M., Bensoussan, A., Wu, E., & Smith, C. A. (2008). Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database of Systematic Reviews, (2), CD005288. https://doi.org/10.1002/14651858.CD005288.pub3
This page is for education. It does not diagnose or treat any condition and is not a substitute for care from a physician or a licensed practitioner. Do not take herbs without guidance from a qualified herbalist, especially if you are pregnant or take prescription medication.